Scholarlink

Background <p>This study aimed to explore the association between sarcopenic obesity (SO) and advanced stages of cardiovascular-kidney-metabolic (CKM) syndrome, as well as to prospectively examine its relationship with cardiovascular events in CKM stages 0–3.</p> Methods <p>Data were drawn from the China Health and Retirement Longitudinal Study (2011–2020) encompassing a median follow-up of 9.0 years for incident cardiovascular events. Sarcopenia was defined according to the Asian Working Group for Sarcopenia 2019 criteria. Non-sarcopenic participants with optimal body mass index or waist circumference served as the reference group. Outcome was major adverse cardiovascular events (MACEs) defined as a composite of all-cause death, cardiovascular problem, and stroke. Multivariable logistic regression and Cox proportional hazards models were employed to assess associations.</p> Results <p>A total of 6,766 participants (age 60.0 ± 9.9 years, 46.9% male) were included. At baseline, SO was associated with a significantly higher likelihood of advanced CKM stages [OR (95% CI): 3.317 (2.533, 4.345)] compared to reference. Similarly, sarcopenic overweight [OR (95% CI): 3.171 (2.601, 3.865)] and sarcopenic abdominal obesity [OR (95% CI): 3.268 (2.662, 4.013)] were also linked to higher odds of advanced CKM stages. Over a median follow-up of 9.0 years, 1,322 participants (21.1%) from CKM stages 0–3 experienced MACEs. After adjusting for multiple covariates, SO was associated with an increased risk of MACEs [HR (95% CI): 2.248 (1.789, 2.824)] compared to reference. Similarly, sarcopenic overweight [HR (95% CI): 1.768 (1.465, 2.135)] and sarcopenic abdominal obesity [HR (95% CI): 1.730 (1.414, 2.115)] were also associated with an elevated risk of MACEs.</p> Conclusions <p>SO was significantly associated with more advanced stages of the CKM spectrum. Furthermore, among individuals categorized with CKM stages 0–3 and without pre-existing cardiovascular disease, SO was independently associated with a substantially elevated risk of future MACEs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Associations between sarcopenic obesity and the risk of cardiovascular-kidney-metabolic syndrome progression: insights from the China health and retirement longitudinal study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月29日

查看全文
  • Yijing Xin,
  • Xifeng Qian,
  • Yanmin Yang

摘要

Background

This study aimed to explore the association between sarcopenic obesity (SO) and advanced stages of cardiovascular-kidney-metabolic (CKM) syndrome, as well as to prospectively examine its relationship with cardiovascular events in CKM stages 0–3.

Methods

Data were drawn from the China Health and Retirement Longitudinal Study (2011–2020) encompassing a median follow-up of 9.0 years for incident cardiovascular events. Sarcopenia was defined according to the Asian Working Group for Sarcopenia 2019 criteria. Non-sarcopenic participants with optimal body mass index or waist circumference served as the reference group. Outcome was major adverse cardiovascular events (MACEs) defined as a composite of all-cause death, cardiovascular problem, and stroke. Multivariable logistic regression and Cox proportional hazards models were employed to assess associations.

Results

A total of 6,766 participants (age 60.0 ± 9.9 years, 46.9% male) were included. At baseline, SO was associated with a significantly higher likelihood of advanced CKM stages [OR (95% CI): 3.317 (2.533, 4.345)] compared to reference. Similarly, sarcopenic overweight [OR (95% CI): 3.171 (2.601, 3.865)] and sarcopenic abdominal obesity [OR (95% CI): 3.268 (2.662, 4.013)] were also linked to higher odds of advanced CKM stages. Over a median follow-up of 9.0 years, 1,322 participants (21.1%) from CKM stages 0–3 experienced MACEs. After adjusting for multiple covariates, SO was associated with an increased risk of MACEs [HR (95% CI): 2.248 (1.789, 2.824)] compared to reference. Similarly, sarcopenic overweight [HR (95% CI): 1.768 (1.465, 2.135)] and sarcopenic abdominal obesity [HR (95% CI): 1.730 (1.414, 2.115)] were also associated with an elevated risk of MACEs.

Conclusions

SO was significantly associated with more advanced stages of the CKM spectrum. Furthermore, among individuals categorized with CKM stages 0–3 and without pre-existing cardiovascular disease, SO was independently associated with a substantially elevated risk of future MACEs.